메뉴 건너뛰기
OncoImmunology
Volumn 2, Issue 1, 2013, Pages
Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901
Author keywords

Biomarkers; Cancer; Immunomonitoring; Immunotherapy; Low dose cyclophosphamide; Peptides; Randomized clinical trial; Regulatory T cells; Renal cell cancer; T cells; Vaccine
Indexed keywords

APOLIPOPROTEIN A1; CYCLOPHOSPHAMIDE; IMA 901; PEPTIDE VACCINE; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;
EID: 84880936480     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22246     Document Type: Article
Times cited : (31)
References (7)
  • 1
    • 77955066199 scopus 로고    scopus 로고
    • IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    • PMID:20818862
    • Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294.
    • (2010) N Engl J Med , vol.363 , pp. 411-422
    • Kantoff, P.W.1    Higano, C.S.2    Shore, N.D.3    Berger, E.R.4    Small, E.J.5    Penson, D.F.6
  • 2
    • 79957831345 scopus 로고    scopus 로고
    • gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma
    • PMID:21631324
    • Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364:2119-27; PMID:21631324; http://dx.doi.org/10.1056/NEJMoa1012863.
    • (2011) N Engl J Med , vol.364 , pp. 2119-2127
    • Schwartzentruber, D.J.1    Lawson, D.H.2    Richards, J.M.3    Conry, R.M.4    Miller, D.M.5    Treisman, J.6
  • 3
    • 79958264390 scopus 로고    scopus 로고
    • Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma
    • PMID:21632504
    • Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011; 29:2787-94; PMID:21632504; http://dx.doi.org/10.1200/JCO.2010.33.3005.
    • (2011) J Clin Oncol , vol.29 , pp. 2787-2794
    • Schuster, S.J.1    Neelapu, S.S.2    Gause, B.L.3    Janik, J.E.4    Muggia, F.M.5    Gockerman, J.P.6
  • 4
    • 84864662070 scopus 로고    scopus 로고
    • Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
    • In Press; PMID
    • Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; In Press; PMID:22842478; http://dx.doi.org/10.1038/nm.2883.
    • (2012) Nat Med , pp. 22842478
    • Walter, S.1    Weinschenk, T.2    Stenzl, A.3    Zdrojowy, R.4    Pluzanska, A.5    Szczylik, C.6
  • 5
    • 0037108856 scopus 로고    scopus 로고
    • Integrated functional genomics approach for the design of patient-individual antitumor vaccines
    • PMID:12384544
    • Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 2002; 62:5818-27; PMID:12384544.
    • (2002) Cancer Res , vol.62 , pp. 5818-5827
    • Weinschenk, T.1    Gouttefangeas, C.2    Schirle, M.3    Obermayr, F.4    Walter, S.5    Schoor, O.6
  • 6
    • 58149179532 scopus 로고    scopus 로고
    • Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients
    • PMID:18927310
    • Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008; 14:6674-82; PMID:18927310; http://dx.doi.org/10.1158/1078-0432.CCR-07-5212.
    • (2008) Clin Cancer Res , vol.14 , pp. 6674-6682
    • Finke, J.H.1    Rini, B.2    Ireland, J.3    Rayman, P.4    Richmond, A.5    Golshayan, A.6
  • 7
    • 63549105681 scopus 로고    scopus 로고
    • Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients
    • PMID:19276286
    • Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15:2148-57; PMID:19276286; http://dx.doi.org/10.1158/1078-0432.CCR-08-1332.
    • (2009) Clin Cancer Res , vol.15 , pp. 2148-2157
    • Ko, J.S.1    Zea, A.H.2    Rini, B.I.3    Ireland, J.L.4    Elson, P.5    Cohen, P.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.